Intellipharmaceutics shares crushed as FDA experts snub pain drug; Moncef Slaoui joins Moderna board
→ After getting chastised by regulators in an internal FDA review of Toronto-based Intellipharmaceutics‘ $IPCI new pain drug Rexista, a panel of outside experts joined …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.